May. 7 at 2:28 PM
$KZR Equity Corporate Actions Alert #2026 - 307
Information Regarding the Tender Offer of Kezar Life Sciences, Inc. (KZR)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-307
The tender offer by Aurinia Pharmaceuticals Inc.
$AUPH to acquire all of the outstanding common stock of Kezar Life Sciences, Inc.
$KZR is scheduled to expire at 11:59 p.m. ET, on May 8, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on May 11, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 8, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 11th) and will be suspended effective May 12, 2026.
KZR shareholders will receive
$6.955 & one non-transferable CVR for each share held.
